Skip to content

Biocon shares jump 2% after UK approval to diabetes drug

So far in 2024, the stock has rallied over 2 percent, marginally outperforming benchmark Nifty which has tisden around 12 percent during this period.

Read More

​ So far in 2024, the stock has rallied over 2 percent, marginally outperforming benchmark Nifty which has tisden around 12 percent during this period. So far in 2024, the stock has rallied over 2 percent, marginally outperforming benchmark Nifty which has tisden around 12 percent during this period.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish